Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry

Neil Lawrence, Irina Bacila, Jeremy Dawson, Jillian Bryce, Salma R. Ali, Erica L.T. van den Akker, Tânia A.S.S. Bachega, Federico Baronio, Niels H. Birkebæk, Walter Bonfig, Hedi C. van der Grinten, Eduardo C. Costa, Liat de Vries, Heba Elsedfy, Ayla Güven, Sabine Hannema, Violeta Iotova, Hetty J. van der Kamp, María Clemente, Corina R. LichiardopolTatjana Milenkovic, Uta Neumann, Ana Nordenström, Şukran Poyrazoğlu, Ursina Probst-Scheidegger, Luisa De Sanctis, Rieko Tadokoro-Cuccaro, Ajay Thankamony, Ana Vieites, Zehra Yavaş, Syed Faisal Ahmed, Nils Krone*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
39 Downloads (Pure)


Objective: Congenital adrenal hyperplasia (CAH) requires exogenous steroid replacement. Treatment is commonly monitored by measuring 17-OH progesterone (17OHP) and androstenedione (D4). Design: Retrospective cohort study using real-world data to evaluate 17OHP and D4 in relation to hydrocortisone (HC) dose in CAH patients treated in 14 countries. Patients: Pseudonymized data from children with 21-hydroxylase deficiency (21OHD) recorded in the International CAH Registry. Measurements: Assessments between January 2000 and October 2020 in patients prescribed HC were reviewed to summarise biomarkers 17OHP and D4 and HC dose. Longitudinal assessment of measures was carried out using linear mixed-effects models (LMEM). Results: Cohort of 345 patients, 52.2% female, median age 4.3 years (interquartile range: 3.1–9.2) were taking a median 11.3 mg/m2/day (8.6–14.4) of HC. Median 17OHP was 35.7 nmol/l (3.0–104.0). Median D4 under 12 years was 0 nmol/L (0–2.0) and above 12 years was 10.5 nmol/L (3.9–21.0). There were significant differences in biomarker values between centres (p < 0.05). Correlation between D4 and 17OHP was good in multiple regression with age (p < 0.001, R2 = 0.29). In longitudinal assessment, 17OHP levels did not change with age, whereas D4 levels increased with age (p < 0.001, R2 = 0.08). Neither biomarker varied directly with dose or weight (p > 0.05). Multivariate LMEM showed HC dose decreasing by 1.0 mg/m2/day for every 1 point increase in weight standard deviation score. Discussion: Registry data show large variability in 17OHP and D4 between centres. 17OHP correlates with D4 well when accounting for age. Prescribed HC dose per body surface area decreased with weight gain.

Original languageEnglish
Pages (from-to)551-561
Number of pages11
JournalClinical Endocrinology
Issue number5
Early online date3 Jul 2022
Publication statusPublished - Nov 2022

Bibliographical note

Funding information
Seventh European Union Framework Program,
Grant/Award Number: 201444; Diurnal Ltd,
Grant/Award Number: Unrestricted Education
Grant; National Institute for Health Research,
Grant/Award Number: Academic Clinical
Fellowship for NRL; University of Glasgow,
Grant/Award Number: Gardiner Lectureship;
Neurocrine Biosciences, Grant/Award Number:
Unrestricted Education Grant; European
Society for Paediatric Endocrinology Research
Unit; Medical Research Council,
Grant/Award Number: G1100236

Publisher Copyright:
© 2022 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.


Dive into the research topics of 'Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry'. Together they form a unique fingerprint.

Cite this